RecruitingNCT03966443
Fluciclovine PET/CT in Multiple Myeloma Patients
PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose
Sponsor
Oslo University Hospital
Enrollment
10 participants
Start Date
Mar 1, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Multiple myeloma patients suitable for ASCT treatment
Exclusion Criteria1
- Patients with contraindications to ASCT treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03966443
Related Trials
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
NCT050913721 location
Feasibility of a Multi-omics Platform for Hematological Malignancies
NCT074454381 location
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT0565193222 locations
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
NCT042681992 locations
e-Motion : Promoting Emotion Regulation in Chronic Cancer
NCT072360212 locations